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Several isolates of Mycobacterium species related to the M. terrae complex have been isolated 
from clinical samples. In the clinical microbiology laboratory, partial 16S rRNA gene sequencing 
(approximate first 500 base pairs) is often used to identify Mycobacterium species rather than full 
16S rRNA gene sequencing. Partial 16S rRNA gene sequence analysis revealed 100% identity 
between 65 clinical isolates and Mycobacterium species MCRO 6 (GenBank accession no. 
X93032). Even after sequencing the nearly full 16S rRNA gene, the closest match to an existing 
type strain is only 99.6% similar toM. nonchromogenicum (ATCC 19530T). Sequencing of the 
nearly full 16S rRNA gene, the 16S-23S internal transcribed spacer region, and the hsp65 gene 
did not reveal genotypic identity with the type strains ofM. nonchromogenicum, M. terrae, or M. 
triviale. Although sequence analysis suggests a unique non-established species, mycolic acid 
analysis by HPLC does not distinguish these clinical isolates from M. nonchromogenicum. To 
further characterize this unique species, phenotypic analysis including growth characteristics, 
susceptibility testing, and biochemical testing was performed. It is proposed that the strain be 
recognized as a novel species of Mycobacteria, Mycobacterium arupense sp. nov., the type strain 
of which is ATCC BAA-1242 (=DSM 44942).
INTRODUCTION
The genus Mycobacterium consists of 120 validly named species at the time of this document, 31 
of which have been described and accepted within the last 5 years
(http://www.dsmz.de/species/bacteria.htm). Despite this rapid increase in the number of newly 
described Mycobacterium species, additional Mycobacterium species will always need to be 
formally described (Pauls et al., 2003; Tortoli, 2003; Turenne et al., 2004). Furthermore, many of 
these un-named species are isolated from clinical specimens and need to be correctly identified 
for proper patient management.
In the clinical microbiology laboratory, phenotypic and biochemical testing may not accurately 
identify Mycobacterium species as the results of these tests may vary depending on growth 
conditions and the judgment of the laboratorian. Sequencing the 16S rRNA gene of 
Mycobacterium species in the clinical laboratory has improved the speed and accuracy of 
identification (Cloud et al., 2002; Turenne et al., 2001; Patel et al., 2000). Sequencing additional 



































increased our ability to describe novel species (Turenne et al., 2004; Tortoli, 2003; Ringuet et al., 
1999; Mohamed et al., 2005).
The purpose of this study was to describe a novel species of Mycobacterium that appears to be a 
genotypic match to Mycobacterium species MCRO 6 from the GenBank database (accession 
number X93032). Species MCRO 6 is genotypically related to the M. terrae complex which 
includesM. terrae, M. nonchromogenicum, andM. triviale (Lee et al., 2004). Over a 5-year 
period, our laboratory has isolated and identified by partial 16S rRNA gene sequencing (positions 
24 to 527 of the Escherichia coli sequence) a genotypic match to this species from 65 human 
specimens. Several investigators have reported ‘MCRO 6’ being isolated from human specimens 
and leading us to believe the organism is clinically relevant (Torkko et al., 1998; Pauls et al., 
2003; Lee et al., 2004). We hereby propose the name Mycobacterium arupense for MCRO 6 and 
present its description.
METHODS
Bacterial strains and growth conditions. Independent data was generated from four separate 
patient samples (tendon, bronchial wash, sputum, and a finger wound) designated as AR30097T, 
AR31431, AR08316, and AR30818, respectively. Strain AR30097T shares the same partial 16S 
rRNA gene sequence and culture characteristics as 64 other isolates of MCRO 6 recovered from 
patient specimens in our lab, all matching perfectly to “MCRO 6” (GenBank accession number 
X93032). Strain AR08316 was included as a rare genetic variant of this group; being isolated 
from sputum and growing slower than AR30097T or AR31431 at room temperature, 30oC, and 
37oC. Toward the end of the study, AR30818 was isolated from a finger of a patient showing 
signs of infection and, therefore, was added for sequence comparison and susceptibility testing. 
Because interpretation of the endpoint of the susceptibility testing procedure, 4 additional isolates 
(8 total) were tested for susceptibility patterns to account for variations that may be observed. The 
strains are described herein as Mycobacterium arupense and strain AR30097T will be referred to 
as ATCC BAA-1242t . The following reference strains were also included in the study for 
comparison: M. terrae ATCC 15755T, M. nonchromogenicum ATCC 19530T, andM. triviale 
ATCC 23292t (=TMC 1453). All strains had been stored at -70°C in Middlebrook 7H9 broth 




































Phenotypic properties. Culture characteristics and biochemical tests listed in Table 1 were 
performed on the 3 original isolates ofM. arupense (AR30097T, AR31431, and AR08316) as 
previously described (Vincent et al., 2002). For comparison, phenotypic properties forM.
nonchromogenicum, M. terrae, and M. triviale were retrieved from Bergey’s Manual of 
Systematic Bacteriology (Wayne & Kubica, 1986).
Susceptibility testing was performed using Sensititre microdilution plates for slowly growing 
nontuberculous mycobacteria (TREK Diagnostics Systems, Inc.), according to CLSI (formerly 
NCCLS) guidelines. The following drugs were tested: ciprofloxacin, gatifloxacin, moxifloxacin, 
linezolid, rifampin, rifabutin, trimethoprim/sulfamethoxazole, ethambutol, clarithromycin, 
amikacin, and streptomycin. Isolates were tested at a final organism density of approximately 5 x 
105 organisms per milliliter. Plates were sealed and incubated in plastic bags at 30°C until 
growth was adequate for interpretation (5-10 days). Minimum inhibitory concentration (MIC) 
was determined to be the lowest concentration of drug to inhibit the amount of visible growth as 
observed in the control well. An exception was made for interpretation of 
trimethoprim/sulfamethoxazole, for which the MIC was determined at 80% inhibition of growth 
compared to the control well.
HPLC. Mycolic acids were prepared, esterified, and analyzed by fluorescence detection high- 
performance liquid chromatography (FL-HPLC) as previously described (Brown et al., 1999; 
Wallace et al., 2002). HPLC reference strains includedM. intracellulare ATCC 13950T as well as 
those described above under the heading “bacterial strains and growth conditions”.
16S rRNA gene, hsp65 gene, and ITS1 sequencing. DNA was extracted from organisms in 
pure culture using the PrepMan Ultra reagent (Applied BioSystems) and frozen at -20oC until 
analysis (1-3 days). Sequencing of real-time PCR amplicons was performed after attainment of 
appropriate melting temperatures determined with Sybr Green™ dye.
Primers used for PCR of their respective targets are listed in table 2. The same primers were used 
for both PCR and sequencing reactions. PCR was performed in a total volume of 40 ^l 
containing: 0.5 .^M each forward and reverse primer, 3 mM MgCl2, and 1X LightCycler® 
FastStart DNA MasterPLUS SYBR Green I prepared according to the manufacturer’s instructions 
(Roche Diagnostics). Annealing temperatures were optimized to be 55oC for 16S rDNA, 55oC for 



































95oC for activation of the polymerase contained in the master mix. Thirty-five cycles of PCR 
were performed for 16S rDNA and ITS1 sequencing while 50 cycles were performed for hsp65. 
The remaining thermal cycling protocol consisted of denaturation (35 s at 96oC), annealing (20 s 
at annealing temperature), and extension (30s at 72oC), with a single final extension (5 min at 
72oC). The melting protocol consisted of stepping 0.5 degree per second from 75oC to 99oC. 
Reactions took place in a RotorGene 3000 (Corbett Research). Melting peaks were analyzed with 
the Rotor-Gene3000 software package version 6.
The PCR products were column-purified using Microcon-100 columns (Amicon). The purified 
amplicons were sequenced by standard methods using the ABI Prism BigDye Terminator v3.0 
Ready Reaction Cycle Sequencing Kit and the ABI Prism 3100 Avant Genetic Analyzer. The 
nucleotide sequences of both forward and reverse DNA strands were determined. If there were 
more than 2% base differences between the strands, sequencing was repeated. Sequence editing, 
alignments, and phylogenetic analyses were performed using the SEQMAN and MEGALIGN 
components of DNASTAR (Lasergene 5). Alignment methods included CLUSTAL V (neighbor- 
joining method) and CLUSTAL W (Thompson et al., 1994).
Some strains revealed numerous ambiguous bases within the edited, quality-controlled ITS1 
sequences and therefore suggested the presence of multiple rrn operons. If more than 2% 
ambiguities occurred due to this phenomenon, cloning of the ITS 1 region was performed by 
standard protocols using a TA Cloning kit (Invitrogen). PCR and sequencing, was performed on 
the clones using the M13 primers from the kit to produce unambiguous sequences. All sequences 
were trimmed at the ITS1 primers before phylogenetic analysis was performed.
Nucleotide sequence accession numbers. The 16S rRNA gene sequence (E. coli bases 37 to 
1446) of M. arupense ATCC BAA-1242T (= DMS 44942T) has been deposited in GenBank under 
accession number DQ157760. The hsp65 gene and 16S-23S internal transcribed spacer (ITS) 1 
region has been deposited in GenBank under accession numbers DQ168662 and DQ168663, 
respectively.
RESULTS AND DISCUSSION 
Phenotypic properties
All phenotypic studies were performed on BAA-1242T, AR31431, and AR08316 with full 


































stained acid-fast, revealing straight to slightly curved bacilli with moderate beading. Growth was 
observed from 22oC to 37oC (table 1) with optimal growth at 30oC. There was no growth at 42oC. 
Growth rate was considered rapid at 30oC with colonies appearing after 5-6 days, while growth 
was slow at 37oC, as colonies did not appear until after 10-11 days. Results of pyrazinamidase 
testing for M. arupense were negative among the 3 strains whereas Torkko reported that 6 of 7 
strains of MCRO 6 were positive (Torkko et al., 1998). Lee did not report results of 
pyrazinamidase testing among the clinical strains of MCRO 6 (Lee et al., 2004). The remaining 
phenotypic properties ofM. arupense revealed similarity with M. nonchromogenicum and M. 
terrae.
Susceptibility testing
MIC results were taken from panels incubated at 30oC. All 8 M. arupense isolates were 
susceptible to rifabutin (3 each with an MIC of 0.5 and 0.25 pg/ml and 2 with an MIC of 0.12 
pg/ml) and ethambutol (7 with an MIC of 0.5 pg/ml and 1 with an MIC of 1.0 pg/ml). All 
isolates except one (MIC of 64 pg/ml) were susceptible to clarithromycin (2 each with an MIC of
4, 2, and 1 pg/ml, and 1 with an MIC of 0.5 pg /ml). Susceptibility to amikacin was variable (3 
each with an MIC of 16 and 32 pg/ml, 1 with an MIC of 64 pg/ml, and 1 with an MIC of > 128 
pg/ml). All isolates were considered resistant to ciprofloxacin (all with an MIC > 32 pg/ml), 
linezolid (6 with an MIC > 128 pg/ml and 2 with an MIC of 64 pg/ml), rifampin (4 with an MIC 
> 16 pg/ml and 4 with an MIC of 8 pg/ml), and streptomycin (4 with an MIC > 64 pg/ml and 4 
with an MIC of 32 pg/ml). Six of eight isolates were resistant to trimethoprim/sulfamethoxazole 
(5 with an MIC > 8/152 pg/ml and 1 each with an MIC of 4/76, 2/38, and 1/19 pg/ml). All 
isolates had an MIC > 16 pg/ml for gatifloxacin and moxifloxacin.
Mycolic acid analysis by FL-HPLC
Three clinical isolates ofM. arupense were compared to M. nonchromogenicum (ATCC 19530T), 
M. terrae (ATCC 15755T), M. triviale (ATCC 23292T), and a clinical isolate forM. triviale 
(B02SA22682) for FL-HPLC analysis. The isolates ofM. arupense yielded mycolic acid 
chromatograms that were typical of Mycobacterium species. All produced a pattern of two 
closely clustered sets of peaks (Fig. 1). This pattern was indistinguishable from the pattern 
produced byM. nonchromogenicum. It was separable from the pattern of the control strain ofM. 



































Sequencing of the 16S rRNA gene, hsp65 gene, and ITS1 region
The 16S rRNA gene was sequenced to near completeness (bases 37-1446 of Escherichia coli 
sequence) for 4 strains ofM. arupense (ATCC BAA-1242T, AR31431, AR08316, and AR30818) 
as well as the reference strains for species of the M. terrae complex, ATCC 19530T (M. 
nonchromogenicum), ATCC 15755T (M. terrae), and ATCC 23292T (M. triviale). Except for 2 
ambiguous bases (N) at positions 938 and 939, the nearly complete 16S rRNA gene sequence of 
ATCC BAA-1242t , AR31431, AR08316, and AR30818 revealed an identical match with 
Mycobacterium sp. MCRO 6 (GenBank accession X93932). Using type strains of validly 
accepted species, the closest relative is M. nonchromogenicum (99.6% similarity; 5 base 
mismatches). As shown in table 3 and figure 3,M. terrae (98.0% similarity; 27 mismatches) and 
M. triviale (95.9% similarity; 56 mismatches) have a more distant genotypic relationship withM. 
arupense.
The sequence of M. arupense has a long helix 18 in the hypervariable region V3 that is 
commonly seen with slow growing Mycobacterium species (Turenne et al., 2004), and 
occasionally seen with rapid growing Mycobacterium species (Menendez et al., 2002). Our 
observations suggestM. arupense is slow growing at 37oC, but rapid growing at 30oC. Therefore, 
we describe M. arupense sp. nov. as moderately growing.
The hsp65 gene (401 nt region) of the type strain ofM. arupense (ATCC BAA-1242T) revealed a 
sequence significantly different from strains of the M. terrae complex (table 3; figure 4). 
AR31431 and AR30818 matched M. arupense perfectly. The variant strain ofM. arupense, 
AR08316, showed only 2 nt mismatches as compared to the most closely related established 
species, M. nonchromogenicum, with 25 nt mismatches.
Some laboratories are using ITS1, rather than 16S rRNA gene, for identification of 
Mycobacterium species because 16S rDNA shows fewer polymorphic sites, which sometimes 
leads to interspecies homogeneity (Mohamed et al., 2005; Roth et al., 1998). For new species 
descriptions, ITS1 data should be included along with that of the 16S rRNA gene. ITS1 shows 
many polymorphic sites between species, but also shows intraspecies heterogeneity due to 
interoperon heterogeneities among species from which multiple rrn operons exist (Ji et al., 1994; 
Roth et al., 1998; Menendez et al., 2002). With ITS1 sequencing, we detected interoperon 
heterogeneities with some strains of M. arupense as well as the reference strain for M. 



































strain ATCC BAA-1242T, but the ITS1 sequences for strain AR31431, AR08316, and ATCC 
19530T showed several ambiguous bases, requiring cloning to obtain sequence from a single copy 
(supplemental figure B).
Even with the number of polymorphisms observed, comparing a single clone of strain AR31431 
resulted in only 5 (of 346) nucleotide mismatches (1.4% divergence) with ATCC BAA-1242T 
(table 3). Strain AR30818 had no polymorphisms and only 1 nucleotide difference from M. 
arupense (ATCC BAA-1242T). All strains ofM. arupense showed relatively low numbers of nt 
mismatches from the type strain compared to reference strains of the M. terrae complex (table 3).
Studies by Roth et al. showed that the lowest ITS1 sequence divergence between any two 
Mycobacterium species was at least 4% (Roth et al., 1998). Although using the sequence of only 
one clone, the sequence of AR08316 revealed 20 nt mismatches from ATCC BAA-1242T, or 
5.8% (20 of 346 nt). Based on other phenotypic and genotypic properties, we would identify the 
genetic variant AR08316 asM. arupense even though we observed a 5.8% ITS1 sequence 
divergence from ATCC BAA-1242T.
We did not obtain all possible clones of each species due to limited resources, but based on our 
findings there are at least 2 rrn operons. Intraspecies heterogeneity has been reported previously 
among strains of the M. terrae complex (Lee et al., 2004). Early reports of intraspecies spacer 
sequence polymorphisms has been suspected to occur more often in rapidly growing than in 
slowly growing mycobacteria (Roth et al., 2000; Roth et al., 1998; Turenne et al., 2001). 
Menendez et al., however, showed it is unlikely that the number of operons or length of helix 18 
is related to the growth rate (Menendez et al., 2002).
Clinical relevance
NTM are ubiquitous in the environment, therefore, it would not be uncommon to find NTM in 
clinical cultures as contaminants. The NTM gain access to the human body through the 
respiratory tract, the gastrointestinal tract, and direct inoculation into skin and soft tissues 
(Shinners & H. Yeager, 1999). We have recovered several isolates ofM. arupense, sp. nov. from 
clinical cultures of respiratory samples, as well as from various other sources including a tendon, 
a finger, synovial fluid, pleural fluid, urine, and stool. These isolates have all been identified by 


































In our laboratory, most (48 of 65) specimens were from sputum or bronchial wash, 8 originated 
from sterile sites (lymph node, lung biopsy, pleural fluid, surgical tissues, and urine), 4 were from 
stool or duodenal contents, and 5 were from unknown sites. In the study by Pauls et al., clinical 
sources of 7 positive cultures for MCRO 6 (M. arupense, sp. nov.) included only 3 sputum 
samples. The remaining 4 samples were suspected to be clinically significant and originated from 
the sterile body sites of brain (1), lung biopsies (2) and pleural fluid (1) (Pauls et al., 2003). More 
clinical information from patient charts should be obtained to gain insight into the clinical 
significance of this organism. Regardless of clinical significance, the organism is being isolated 
quite commonly in the clinical laboratory and therefore needs to be validly described.
Description of Mycobacterium arupense sp. nov.
Mycobacterium arupense is a nonchromogenic acid-fast bacillus growing rapidly (5-7 days) on 
Lowenstein-Jensen medium at 30oC and, slowly (10-12 days) at 37oC. Isolates do not grow on 
MacConkey agar lacking crystal violet and are positive for 68oC catalase, 14-day arylsulfatase, 
and tween-80 hydrolysis; and negative for niacin, nitrate reductase, 3-day arylsulfatase, urease, 
iron uptake, pyrazinamidase, and tolerance to 5% NaCl. The FL-HPLC mycolic acid pattern is 
indistinguishable from that produced byM. nonchromogenicum. The 16S rRNA gene sequence 
(GenBank Accession No. DQ157760) reveals a unique species unlike any established species and 
most similar to the reference strainM. nonchromogenicum (ATCC 19530T).
The type strain, ATCC BAA-1242 (=DSM 44942), was representative of 65 human isolates 
studied in our laboratory over a 5-year period. Several isolates appeared to be clinically 
significant and were treated with antimicrobials. The isolates were generally susceptible to 
ethambutol, clarithromycin, and rifabutin while resistant to rifampicin, linezolid, streptomycin, 
and the quinolones.
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268 Table 1. Comparison of biochemical characteristics ofM. arupense clinical strains and the
269 closely related species of the M. terrae complex.






Growth at 22oC + + + +
Growth at 30oC + + + +
Growth at 37oC + + + +
Growth at 42oC - v - -
Pigmentation N N N N
Niacin accumulation* - - - -
Nitrate reduction* - - v +
68oC catalase* + + + +
3-day arylsulfatase - - - +
14-day arylsulfatase + + + +
Tween-80 hydrolysis* + + + +
Iron uptake - - - -
Growth on MacConkey 
without crystal violet
Urease activity - - - -
Tolerance to 5% NaCl* - - - +
Pyrazinamidase* - + - -
*Data for reference species (M. nonchromogenicum, M. terrae, and M. triviale) were ta ken from
271 Wayne and Kubica (1986). v, variable; N, nonchromogenic.
272
272  Table 2. Primers used for sequence-based studies.
Name Gene Target Sequence (5’-3’) Source
16S-27f 16S rRNA AGAGTTTGATCMTGGCTCAG Mellmann et al.
16S-519r 16S rRNA GWATTACCGCGGCKGCTG Mellmann et al.
16S-359f 16S rRNA CTCCTACGGGAGGCAGCAGT Vaneechoutte et al.
16S-971r 16S rRNA CTCTGCCGGCGTCCTGT This study
16S-895f 16S rRNA CGGCGGAGCATGTGGATTA This study
16S-1482r 16S rRNA CACCTTCCGGTACGGCTACCT This study
Tb11 hsp65 ACCAACGATGGTGTGTCCAT Telenti et al.
Tb12 hsp65 CTTGTCGAACCGCATACCCT Telenti et al.
ITS1-1511f ITS1 AAGTCGTAACAAGGTARCCG Turenne et al., 
Harmsen et al.




274 Table 3. Sequence analysis describing the number of nucleotide differences from M. arupense
275 sp. nov. (ATCC BAA-1242T) existing with each of the strains in the study.
Strain 16S rRNA hsp65 ITS1
M. arupense (AR30818) 0 0 1
M. arupense (AR31431) 0 0 5*
M. arupense (AR08316) 0 2 20*
M. nonchromogenicum (ATCC 19530T) 5 25 60
M. terrae (ATCC 15755T) 27 31 66
M. triviale (ATCC 23292T) 56 54 144








Figure 1. FL-HPLC chromatograms for comparison among strains. A, M. intracellulare ATCC 
13950t ; B, M. terrae ATCC 15755T; C, M. triviale ATCC 23292T; D, M. triviale clinical isolate 
B02SA22682; E, M. nonchromogenicum ATCC 19530t ; F, ATCC BAA-1242t ; G, AR08316; H, 
AR31431.
282 Figure 2. Sequence comparison among Mycobacterium species of interest for the 16S rRNA
283 gene hypervariable region B (V3) from E. coli positions 428 to 463. Sequences were determined
284 in our lab unless indicated by a GenBank accession number in parentheses.
285
286
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286 Figure 3. Phylogenetic tree of nearly complete 16S rRNA gene (E. coli positions 37 to 1446)
287 sequences showing the genetic relationship among the strains ofM. arupense and strains of the
288 M. terrae complex. The CLUSTAL W method was performed with weightings using the
289 MEGALIGN component of the DNAStar software (Lasergene 5). M. tuberculosis and M.
290 abscessus were included as out-groups. All sequences were determined in our laboratory except
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Figure 4. Phylogenetic positions according to 401 nt of the hsp65 gene sequence of strains ofM. 
arupense in relation to strains of the M. terrae complex. The CLUSTAL W method was 
performed with weightings using the MEGALIGN component of the DNAStar software 
(Lasergene 5). All sequences were determined in our laboratory.
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Supplemental Figure A. Sequence chromatogram showing a region of ambiguities within the 
16S-23S internal transcribed spacer region forM. nonchromogenicum (ATCC 19530T). The 
sequence was determined in our laboratory after several repeat analyses on different cultures to 
rule out a mixed species.
Supplemental Figure B. Alignment of the 16S-23S rRNA spacer (ITS1) sequences of the M. 
arupense strains. The sequence of the type strain, M. arupense (ATCC BAA-1424T), shows 5 
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